vs
Side-by-side financial comparison of Cytek Biosciences, Inc. (CTKB) and RE/MAX Holdings, Inc. (RMAX). Click either name above to swap in a different company.
RE/MAX Holdings, Inc. is the larger business by last-quarter revenue ($71.1M vs $62.1M, roughly 1.1× Cytek Biosciences, Inc.). RE/MAX Holdings, Inc. runs the higher net margin — 2.0% vs -70.9%, a 73.0% gap on every dollar of revenue. On growth, Cytek Biosciences, Inc. posted the faster year-over-year revenue change (8.1% vs -1.8%). RE/MAX Holdings, Inc. produced more free cash flow last quarter ($33.5M vs $-1.8M). Over the past eight quarters, Cytek Biosciences, Inc.'s revenue compounded faster (17.7% CAGR vs -4.7%).
Cytek Biosciences, Inc. develops, manufactures and sells high-performance flow cytometry systems, associated reagents and analysis software. Its solutions serve life science research, clinical diagnostics and biopharmaceutical sectors, with a global customer base across North America, Europe and the Asia-Pacific region.
RE/MAX is an international real estate franchise operating in over 100 countries and territories that, in 2015, had over 100,000 agents in 6,800 offices.
CTKB vs RMAX — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $62.1M | $71.1M |
| Net Profit | $-44.1M | $1.4M |
| Gross Margin | 52.9% | — |
| Operating Margin | -9.0% | 13.1% |
| Net Margin | -70.9% | 2.0% |
| Revenue YoY | 8.1% | -1.8% |
| Net Profit YoY | -557.1% | -75.2% |
| EPS (diluted) | — | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $62.1M | $71.1M | ||
| Q3 25 | $52.3M | $73.2M | ||
| Q2 25 | $45.6M | $72.8M | ||
| Q1 25 | $41.5M | $74.5M | ||
| Q4 24 | $57.5M | $72.5M | ||
| Q3 24 | $51.5M | $78.5M | ||
| Q2 24 | $46.6M | $78.5M | ||
| Q1 24 | $44.9M | $78.3M |
| Q4 25 | $-44.1M | $1.4M | ||
| Q3 25 | $-5.5M | $4.0M | ||
| Q2 25 | $-5.6M | $4.7M | ||
| Q1 25 | $-11.4M | $-2.0M | ||
| Q4 24 | $9.6M | $5.8M | ||
| Q3 24 | $941.0K | $966.0K | ||
| Q2 24 | $-10.4M | $3.7M | ||
| Q1 24 | $-6.2M | $-3.4M |
| Q4 25 | 52.9% | — | ||
| Q3 25 | 52.7% | — | ||
| Q2 25 | 52.3% | — | ||
| Q1 25 | 48.6% | — | ||
| Q4 24 | 58.5% | — | ||
| Q3 24 | 56.3% | — | ||
| Q2 24 | 54.6% | — | ||
| Q1 24 | 51.3% | — |
| Q4 25 | -9.0% | 13.1% | ||
| Q3 25 | -17.6% | 25.0% | ||
| Q2 25 | -23.3% | 19.3% | ||
| Q1 25 | -36.1% | 7.2% | ||
| Q4 24 | 5.2% | 5.9% | ||
| Q3 24 | -8.2% | 19.4% | ||
| Q2 24 | -18.3% | 20.6% | ||
| Q1 24 | -23.9% | 5.8% |
| Q4 25 | -70.9% | 2.0% | ||
| Q3 25 | -10.5% | 5.4% | ||
| Q2 25 | -12.2% | 6.4% | ||
| Q1 25 | -27.5% | -2.6% | ||
| Q4 24 | 16.8% | 8.0% | ||
| Q3 24 | 1.8% | 1.2% | ||
| Q2 24 | -22.4% | 4.7% | ||
| Q1 24 | -13.8% | -4.3% |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $90.9M | $118.7M |
| Total DebtLower is stronger | — | $432.2M |
| Stockholders' EquityBook value | $341.7M | $452.4M |
| Total Assets | $461.5M | $582.5M |
| Debt / EquityLower = less leverage | — | 0.96× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $90.9M | $118.7M | ||
| Q3 25 | $93.3M | $107.5M | ||
| Q2 25 | $75.5M | $94.3M | ||
| Q1 25 | $95.3M | $89.1M | ||
| Q4 24 | $98.7M | $96.6M | ||
| Q3 24 | $162.3M | $83.8M | ||
| Q2 24 | $177.9M | $66.1M | ||
| Q1 24 | $168.8M | $82.1M |
| Q4 25 | — | $432.2M | ||
| Q3 25 | — | $433.3M | ||
| Q2 25 | — | $434.4M | ||
| Q1 25 | — | $435.3M | ||
| Q4 24 | — | $436.2M | ||
| Q3 24 | — | $437.2M | ||
| Q2 24 | — | $438.1M | ||
| Q1 24 | — | $439.0M |
| Q4 25 | $341.7M | $452.4M | ||
| Q3 25 | $378.6M | $448.1M | ||
| Q2 25 | $377.6M | $442.4M | ||
| Q1 25 | $379.6M | $433.5M | ||
| Q4 24 | $395.7M | $429.5M | ||
| Q3 24 | $385.5M | $423.1M | ||
| Q2 24 | $389.1M | $418.4M | ||
| Q1 24 | $392.6M | $412.0M |
| Q4 25 | $461.5M | $582.5M | ||
| Q3 25 | $494.9M | $582.2M | ||
| Q2 25 | $493.3M | $574.8M | ||
| Q1 25 | $482.6M | $571.4M | ||
| Q4 24 | $499.5M | $581.6M | ||
| Q3 24 | $491.2M | $578.6M | ||
| Q2 24 | $483.7M | $571.4M | ||
| Q1 24 | $492.1M | $566.7M |
| Q4 25 | — | 0.96× | ||
| Q3 25 | — | 0.97× | ||
| Q2 25 | — | 0.98× | ||
| Q1 25 | — | 1.00× | ||
| Q4 24 | — | 1.02× | ||
| Q3 24 | — | 1.03× | ||
| Q2 24 | — | 1.05× | ||
| Q1 24 | — | 1.07× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-771.0K | $40.9M |
| Free Cash FlowOCF − Capex | $-1.8M | $33.5M |
| FCF MarginFCF / Revenue | -2.9% | 47.1% |
| Capex IntensityCapex / Revenue | 1.6% | 10.4% |
| Cash ConversionOCF / Net Profit | — | 28.39× |
| TTM Free Cash FlowTrailing 4 quarters | $-8.8M | $56.8M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-771.0K | $40.9M | ||
| Q3 25 | $-3.9M | $17.7M | ||
| Q2 25 | $108.0K | $4.6M | ||
| Q1 25 | $-125.0K | $5.7M | ||
| Q4 24 | $2.0M | $59.7M | ||
| Q3 24 | $13.2M | $17.6M | ||
| Q2 24 | $6.2M | $15.9M | ||
| Q1 24 | $4.0M | $9.4M |
| Q4 25 | $-1.8M | $33.5M | ||
| Q3 25 | $-4.6M | $16.4M | ||
| Q2 25 | $-1.5M | $2.9M | ||
| Q1 25 | $-974.0K | $4.0M | ||
| Q4 24 | $1.1M | $53.0M | ||
| Q3 24 | $12.2M | $16.3M | ||
| Q2 24 | $5.2M | $14.0M | ||
| Q1 24 | $3.4M | $6.8M |
| Q4 25 | -2.9% | 47.1% | ||
| Q3 25 | -8.7% | 22.4% | ||
| Q2 25 | -3.2% | 4.0% | ||
| Q1 25 | -2.3% | 5.3% | ||
| Q4 24 | 1.9% | 73.2% | ||
| Q3 24 | 23.7% | 20.8% | ||
| Q2 24 | 11.0% | 17.8% | ||
| Q1 24 | 7.6% | 8.6% |
| Q4 25 | 1.6% | 10.4% | ||
| Q3 25 | 1.3% | 1.8% | ||
| Q2 25 | 3.5% | 2.2% | ||
| Q1 25 | 2.0% | 2.3% | ||
| Q4 24 | 1.6% | 9.1% | ||
| Q3 24 | 2.0% | 1.7% | ||
| Q2 24 | 2.3% | 2.4% | ||
| Q1 24 | 1.3% | 3.3% |
| Q4 25 | — | 28.39× | ||
| Q3 25 | — | 4.45× | ||
| Q2 25 | — | 0.97× | ||
| Q1 25 | — | — | ||
| Q4 24 | 0.21× | 10.28× | ||
| Q3 24 | 14.05× | 18.22× | ||
| Q2 24 | — | 4.29× | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CTKB
| Products | $46.6M | 75% |
| Services | $15.5M | 25% |
RMAX
| Franchising Segment | $50.1M | 70% |
| Broker Fees | $13.9M | 20% |
| Annual Dues | $7.4M | 10% |
